GigaGen Inc., a biopharmaceutical company developing novel antibody therapies, today announced the United States Patent and Trademark Office has issued U.S. Patent No. 10,329,557, covering methods that enable parallel functional analysis of single cells, a core capability of the company’s Surge™ technology. With its massively parallel single-cell bioassay platform, GigaGen can interrogate complex mixtures of […]
https://gigagen.com/wp-content/uploads/Gigagen_Inline_FullColor_RGB-72-350x95.png00jkellerhttps://gigagen.com/wp-content/uploads/Gigagen_Inline_FullColor_RGB-72-350x95.pngjkeller2019-07-19 07:22:592019-07-20 07:24:04GigaGen Announces Issuance of US Patent for Functional Analysis Methods in the Discovery and Development of Therapeutic Antibodies
There are numerous ways to rank a company as “the best place to work.” Some listings rank companies by pay, others by how “happy and engaged” the workforce is, others by culture and benefits. Some rankings use metrics while others are based on employee surveys. Here’s a look at six San Francisco Bay Area life […]
https://gigagen.com/wp-content/uploads/Gigagen_Inline_FullColor_RGB-72-350x95.png00jkellerhttps://gigagen.com/wp-content/uploads/Gigagen_Inline_FullColor_RGB-72-350x95.pngjkeller2019-04-19 06:32:552019-04-24 06:34:01BioSpace: 6 Award-Winning Life Science Companies in the Bay Area
GigaGen Inc., a biopharmaceutical company developing novel antibody therapies, today announced the publication of a study that shows the feasibility and benefit of its Surge™ antibody discovery and engineering platform for rapid monoclonal antibody discovery using multiple immunization protocols in parallel. The study has been published online in the peer-reviewed scientific journal mAbs, and it […]
https://gigagen.com/wp-content/uploads/Gigagen_Inline_FullColor_RGB-72-350x95.png00jkellerhttps://gigagen.com/wp-content/uploads/Gigagen_Inline_FullColor_RGB-72-350x95.pngjkeller2019-03-25 05:30:542019-03-25 05:31:35GigaGen Publishes Study in Peer-Reviewed Journal mAbs, Validating Feasibility and Benefit of Rapid Parallel Immunization Protocols for Discovery of Novel Monoclonal Antibodies
“What traditions do you want to follow for your baby?” asked the midwife leading our prenatal education group. As we went around the circle of parents-to-be, most couples discussed holiday traditions, camping trips, and weekend routines. When it was my turn to share, I thought about the pseudoscience that had been espoused in this group […]
https://gigagen.com/wp-content/uploads/Gigagen_Inline_FullColor_RGB-72-350x95.png00jkellerhttps://gigagen.com/wp-content/uploads/Gigagen_Inline_FullColor_RGB-72-350x95.pngjkeller2019-03-13 05:41:142019-03-13 05:44:40STAT: GigaGen CEO Dave Johnson, PhD, discusses why biotech execs need to create an environment that fosters a truly scientific culture
GigaGen Inc., a biopharmaceutical company developing novel antibody therapies, today announced that David Johnson, Ph.D., chief executive officer, will present at the 2019 Antibody Engineering & Therapeutics Asia Meeting. Dr. Johnson will also co-chair the presentation, which will take place at 8:45 a.m. JST on February 26, 2019, at the Hilton Tokyo Bay Hotel in […]
https://gigagen.com/wp-content/uploads/Gigagen_Inline_FullColor_RGB-72-350x95.png00jkellerhttps://gigagen.com/wp-content/uploads/Gigagen_Inline_FullColor_RGB-72-350x95.pngjkeller2019-02-25 09:26:572019-02-25 09:26:57GigaGen CEO David Johnson to Present on Surge Technology at 2019 Antibody Engineering & Therapeutics Asia Meeting
GigaGen Inc., a biopharmaceutical company developing novel antibody therapies, today announced the publication of a study showing how it adapted its Surge™ antibody discovery and engineering platform to improve selection of OX40 agonists. The study has been published online in the peer-reviewed scientific journal, Antibodies, as part of the special issue Antibody Repertoire Mining for […]
GigaGen Inc., a biopharmaceutical company developing novel antibody therapies, today announced the promotion of Adam Adler, Ph.D., to Chief Scientific Officer (CSO). Previously, Dr. Adler was the company’s Vice President of Research and Development. In addition, Gigagen has promoted Rena Mizrahi, Ph.D to Vice President of Process Development and Catherine Medina to Vice President of […]
GigaGen Inc., a biopharmaceutical company developing novel antibody therapies, today announced that Erica Stone, Ph.D., has joined the company as director, immuno-oncology. “We welcome award-winning immunologist Dr. Stone to the GigaGen team,” said Dave Johnson, Ph.D., CEO of GigaGen. “Dr. Stone brings with her a deep understanding of the tumor microenvironment and checkpoint inhibitors that […]
GigaGen Inc., a biopharmaceutical company developing novel antibody therapies, today announced that David Johnson, Ph.D., chief executive officer, will present at the 2018 Antibody Engineering & Therapeutics Meeting. Dr. Johnson’s presentation will take place at 3:15 p.m. PST on December 9, 2018, at the Manchester Grand Hyatt in San Diego, Calif. Read the full press […]
https://gigagen.com/wp-content/uploads/Gigagen_Inline_FullColor_RGB-72-350x95.png00jkellerhttps://gigagen.com/wp-content/uploads/Gigagen_Inline_FullColor_RGB-72-350x95.pngjkeller2018-12-07 05:55:582018-12-07 05:55:58GigaGen CEO David Johnson to Present at 2018 Antibody Engineering & Therapeutics Meeting
GigaGen Inc., a biopharmaceutical company developing novel antibody therapies, today announced that David Johnson, Ph.D., Founder and Chief Executive Officer, will present on the development of highly diverse, functional antibodies for infectious disease utilizing Surge technology at the 10th Annual Protein & Antibody Engineering Summit (PEGS) in Europe. Dr. Johnson’s invited podium presentation is titled […]
https://gigagen.com/wp-content/uploads/Gigagen_Inline_FullColor_RGB-72-350x95.png00jkellerhttps://gigagen.com/wp-content/uploads/Gigagen_Inline_FullColor_RGB-72-350x95.pngjkeller2018-11-12 14:36:122018-11-12 14:37:53GigaGen CEO David Johnson to Present on Development of Recombinant Polyclonal Therapies for Infectious Disease at 10th Annual PEGS Summit Europe
GigaGen Inc., a biopharmaceutical company developing novel antibody therapies, today announced a data presentation at the 33rd Annual Meeting of the Society for Immunotherapy of Cancer (SITC). Adam Adler, Ph.D., Vice President of Research and Development, will present on the antibody drug candidates discovered by the company’s industry-leading Surge technology against 17 unique immuno-oncology targets. […]
https://gigagen.com/wp-content/uploads/Gigagen_Inline_FullColor_RGB-72-350x95.png00jkellerhttps://gigagen.com/wp-content/uploads/Gigagen_Inline_FullColor_RGB-72-350x95.pngjkeller2018-11-09 09:17:002018-11-09 09:19:44GigaGen to Present Data on Immuno-Oncology Pipeline at the Society for Immunotherapy of Cancer (SITC) 2018 Annual Meeting
“Scrappy.” That’s a one-word summation of GigaGen’s approach to both the business and science of biotech. “When you’re a new company, you have to be scrappy and clever. When I founded GigaGen in 2011, I didn’t have a big war chest of money, so I had to find a way to be competitive. That’s central […]
GigaGen Inc., a biopharmaceutical company developing novel antibody therapies, today announced a data presentation at the 18th Biennial Meeting of the European Society for Immunodeficiencies (ESID). Rena Mizrahi, Ph.D., director of protein engineering, will present on the company’s proprietary recombinant hyperimmune gammaglobulin program. The conference takes place October 24-27, 2018, at the Centro de Congressos […]
https://gigagen.com/wp-content/uploads/Gigagen_Inline_FullColor_RGB-72-350x95.png00jkellerhttps://gigagen.com/wp-content/uploads/Gigagen_Inline_FullColor_RGB-72-350x95.pngjkeller2018-10-26 07:10:412018-10-26 07:11:16GigaGen to Present Data on Recombinant Hyperimmune Gammaglobulin at the 18th Biennial Meeting of the European Society for Immunodeficiencies
The National Institutes of Health (NIH) is a household name in the drug discovery and development industry. Among the NIH’s many recipients is South San Francisco, Calif.-based GigaGen, a biotherapeutics company. GigaGen’s CEO, Dr. Dave Johnson, took some time to talk with us about how NIH funding and participation in the I-Corps commercialization program helped […]
https://gigagen.com/wp-content/uploads/Gigagen_Inline_FullColor_RGB-72-350x95.png00jkellerhttps://gigagen.com/wp-content/uploads/Gigagen_Inline_FullColor_RGB-72-350x95.pngjkeller2018-08-14 11:06:482018-08-20 11:13:36Drug Discovery News: GigaGen CEO Dave Johnson, PhD, discusses I/O product development and impact of NIH grant support on company growth
https://gigagen.com/wp-content/uploads/Gigagen_Inline_FullColor_RGB-72-350x95.png00jkellerhttps://gigagen.com/wp-content/uploads/Gigagen_Inline_FullColor_RGB-72-350x95.pngjkeller2018-08-03 11:30:022018-08-03 11:31:13GigaGen CEO Dave Johnson interviewed by Moira Gunn on Biotech Nation Radio
Antibodies have been used since the late 1980s as therapies to treat serious diseases, and demand is soaring to new heights today. However, conventional antibody drug discovery technologies are labor-intensive and slow. Pharmaceutical companies select drug candidates from just a small fraction of the antibodies that exist in a natural immune repertoire and have limited […]
https://gigagen.com/wp-content/uploads/Gigagen_Inline_FullColor_RGB-72-350x95.png00jkellerhttps://gigagen.com/wp-content/uploads/Gigagen_Inline_FullColor_RGB-72-350x95.pngjkeller2018-06-06 11:10:312018-06-06 11:10:31Drug Development and Delivery: GigaGen CEO Dave Johnson discusses Why Understanding Immune Dysregulation is the Key to Drug Development
GigaGen Inc., a biopharmaceutical company developing novel antibody therapies, today announced that Sheila M. Keating, Ph.D., has joined the company as Director, Immunology. Dr. Keating will lead clinical development of GigaGen’s recombinant hyperimmune gammaglobulin product in collaboration with pharmaceutical partner Grifols. Read the full press release.
https://gigagen.com/wp-content/uploads/Gigagen_Inline_FullColor_RGB-72-350x95.png00jkellerhttps://gigagen.com/wp-content/uploads/Gigagen_Inline_FullColor_RGB-72-350x95.pngjkeller2018-05-03 08:14:352018-05-03 08:14:35GigaGen Announces Appointment of Sheila M. Keating, Ph.D., as Director, Immunology
GigaGen Inc., a biopharmaceutical company developing novel antibody therapies, today announced that David Johnson, Ph.D., Founder and Chief Executive Officer, will present on the discovery of unique and functional antibodies utilizing Surge technology at the 14th Annual PEGS Summit. Dr. Johnson’s invited podium presentation is titled “Discovery of High-Affinity Human PD-1 and LAG-3 Antibodies Using […]
https://gigagen.com/wp-content/uploads/Gigagen_Inline_FullColor_RGB-72-350x95.png00jkellerhttps://gigagen.com/wp-content/uploads/Gigagen_Inline_FullColor_RGB-72-350x95.pngjkeller2018-04-30 06:02:292018-04-30 06:03:59GigaGen CEO David Johnson to Present on the Power of Surge Technology to Discover Unique Immuno-oncology Antibodies at 14th Annual PEGS Summit
GigaGen Inc., a biopharmaceutical company developing novel antibody therapies, today announced that David Johnson, Ph.D., chief executive officer, will present data from the company’s proprietary Surge platform at the American Association for Cancer Research (AACR) Annual Meeting 2018. The conference will take place April 14-18, 2018, at the McCormick Place in Chicago. Read the full […]
https://gigagen.com/wp-content/uploads/Gigagen_Inline_FullColor_RGB-72-350x95.png00jkellerhttps://gigagen.com/wp-content/uploads/Gigagen_Inline_FullColor_RGB-72-350x95.pngjkeller2018-04-09 09:01:312018-04-09 09:01:31GigaGen CEO David Johnson to Present Data from Surge Platform at American Association for Cancer Research Annual Meeting 2018
Our annual survey highlights how immune-oncology and screens based on the application of cutting-edge omics technologies are providing a launchpad for a succession of startups interrogating biology across biomedicine. Read the full story.
https://gigagen.com/wp-content/uploads/Gigagen_Inline_FullColor_RGB-72-350x95.png00jkellerhttps://gigagen.com/wp-content/uploads/Gigagen_Inline_FullColor_RGB-72-350x95.pngjkeller2018-04-06 07:39:462018-04-06 07:40:42Nature Biotechnology: GigaGen Recognized as One of the Top Biotech Startups Funded in 2017
GigaGen Announces Issuance of US Patent for Functional Analysis Methods in the Discovery and Development of Therapeutic Antibodies
News, UncategorizedGigaGen Inc., a biopharmaceutical company developing novel antibody therapies, today announced the United States Patent and Trademark Office has issued U.S. Patent No. 10,329,557, covering methods that enable parallel functional analysis of single cells, a core capability of the company’s Surge™ technology. With its massively parallel single-cell bioassay platform, GigaGen can interrogate complex mixtures of […]
BioSpace: 6 Award-Winning Life Science Companies in the Bay Area
News, UncategorizedThere are numerous ways to rank a company as “the best place to work.” Some listings rank companies by pay, others by how “happy and engaged” the workforce is, others by culture and benefits. Some rankings use metrics while others are based on employee surveys. Here’s a look at six San Francisco Bay Area life […]
GigaGen Publishes Study in Peer-Reviewed Journal mAbs, Validating Feasibility and Benefit of Rapid Parallel Immunization Protocols for Discovery of Novel Monoclonal Antibodies
News, UncategorizedGigaGen Inc., a biopharmaceutical company developing novel antibody therapies, today announced the publication of a study that shows the feasibility and benefit of its Surge™ antibody discovery and engineering platform for rapid monoclonal antibody discovery using multiple immunization protocols in parallel. The study has been published online in the peer-reviewed scientific journal mAbs, and it […]
STAT: GigaGen CEO Dave Johnson, PhD, discusses why biotech execs need to create an environment that fosters a truly scientific culture
News, Uncategorized“What traditions do you want to follow for your baby?” asked the midwife leading our prenatal education group. As we went around the circle of parents-to-be, most couples discussed holiday traditions, camping trips, and weekend routines. When it was my turn to share, I thought about the pseudoscience that had been espoused in this group […]
GigaGen CEO David Johnson to Present on Surge Technology at 2019 Antibody Engineering & Therapeutics Asia Meeting
News, UncategorizedGigaGen Inc., a biopharmaceutical company developing novel antibody therapies, today announced that David Johnson, Ph.D., chief executive officer, will present at the 2019 Antibody Engineering & Therapeutics Asia Meeting. Dr. Johnson will also co-chair the presentation, which will take place at 8:45 a.m. JST on February 26, 2019, at the Hilton Tokyo Bay Hotel in […]
GigaGen Publishes Study Demonstrating Optimal Method for Selecting OX40 Therapeutic Candidates from Antibody Repertoires
News, UncategorizedGigaGen Inc., a biopharmaceutical company developing novel antibody therapies, today announced the publication of a study showing how it adapted its Surge™ antibody discovery and engineering platform to improve selection of OX40 agonists. The study has been published online in the peer-reviewed scientific journal, Antibodies, as part of the special issue Antibody Repertoire Mining for […]
GigaGen Promotes Adam Adler, Ph.D., to Chief Scientific Officer
News, UncategorizedGigaGen Inc., a biopharmaceutical company developing novel antibody therapies, today announced the promotion of Adam Adler, Ph.D., to Chief Scientific Officer (CSO). Previously, Dr. Adler was the company’s Vice President of Research and Development. In addition, Gigagen has promoted Rena Mizrahi, Ph.D to Vice President of Process Development and Catherine Medina to Vice President of […]
GigaGen Announces Appointment of Erica Stone, Ph.D., as Director, Immuno-Oncology
News, UncategorizedGigaGen Inc., a biopharmaceutical company developing novel antibody therapies, today announced that Erica Stone, Ph.D., has joined the company as director, immuno-oncology. “We welcome award-winning immunologist Dr. Stone to the GigaGen team,” said Dave Johnson, Ph.D., CEO of GigaGen. “Dr. Stone brings with her a deep understanding of the tumor microenvironment and checkpoint inhibitors that […]
GigaGen CEO David Johnson to Present at 2018 Antibody Engineering & Therapeutics Meeting
News, UncategorizedGigaGen Inc., a biopharmaceutical company developing novel antibody therapies, today announced that David Johnson, Ph.D., chief executive officer, will present at the 2018 Antibody Engineering & Therapeutics Meeting. Dr. Johnson’s presentation will take place at 3:15 p.m. PST on December 9, 2018, at the Manchester Grand Hyatt in San Diego, Calif. Read the full press […]
GigaGen CEO David Johnson to Present on Development of Recombinant Polyclonal Therapies for Infectious Disease at 10th Annual PEGS Summit Europe
News, UncategorizedGigaGen Inc., a biopharmaceutical company developing novel antibody therapies, today announced that David Johnson, Ph.D., Founder and Chief Executive Officer, will present on the development of highly diverse, functional antibodies for infectious disease utilizing Surge technology at the 10th Annual Protein & Antibody Engineering Summit (PEGS) in Europe. Dr. Johnson’s invited podium presentation is titled […]
GigaGen to Present Data on Immuno-Oncology Pipeline at the Society for Immunotherapy of Cancer (SITC) 2018 Annual Meeting
News, UncategorizedGigaGen Inc., a biopharmaceutical company developing novel antibody therapies, today announced a data presentation at the 33rd Annual Meeting of the Society for Immunotherapy of Cancer (SITC). Adam Adler, Ph.D., Vice President of Research and Development, will present on the antibody drug candidates discovered by the company’s industry-leading Surge technology against 17 unique immuno-oncology targets. […]
Genetic Engineering & Biotechnology News: Microfluidic dragnet catches most-wanted antibodies – GigaGen exhaustively interrogates antibodies to find drug candidates
News, Uncategorized“Scrappy.” That’s a one-word summation of GigaGen’s approach to both the business and science of biotech. “When you’re a new company, you have to be scrappy and clever. When I founded GigaGen in 2011, I didn’t have a big war chest of money, so I had to find a way to be competitive. That’s central […]
GigaGen to Present Data on Recombinant Hyperimmune Gammaglobulin at the 18th Biennial Meeting of the European Society for Immunodeficiencies
News, UncategorizedGigaGen Inc., a biopharmaceutical company developing novel antibody therapies, today announced a data presentation at the 18th Biennial Meeting of the European Society for Immunodeficiencies (ESID). Rena Mizrahi, Ph.D., director of protein engineering, will present on the company’s proprietary recombinant hyperimmune gammaglobulin program. The conference takes place October 24-27, 2018, at the Centro de Congressos […]
Drug Discovery News: GigaGen CEO Dave Johnson, PhD, discusses I/O product development and impact of NIH grant support on company growth
News, UncategorizedThe National Institutes of Health (NIH) is a household name in the drug discovery and development industry. Among the NIH’s many recipients is South San Francisco, Calif.-based GigaGen, a biotherapeutics company. GigaGen’s CEO, Dr. Dave Johnson, took some time to talk with us about how NIH funding and participation in the I-Corps commercialization program helped […]
GigaGen CEO Dave Johnson interviewed by Moira Gunn on Biotech Nation Radio
News, UncategorizedListen to Moira Gunn’s interview with GigaGen CEO Dave Johnson, PhD, on developing next generation I/O drugs to fight cancer on Biotech Nation Radio
Drug Development and Delivery: GigaGen CEO Dave Johnson discusses Why Understanding Immune Dysregulation is the Key to Drug Development
News, UncategorizedAntibodies have been used since the late 1980s as therapies to treat serious diseases, and demand is soaring to new heights today. However, conventional antibody drug discovery technologies are labor-intensive and slow. Pharmaceutical companies select drug candidates from just a small fraction of the antibodies that exist in a natural immune repertoire and have limited […]
GigaGen Announces Appointment of Sheila M. Keating, Ph.D., as Director, Immunology
News, UncategorizedGigaGen Inc., a biopharmaceutical company developing novel antibody therapies, today announced that Sheila M. Keating, Ph.D., has joined the company as Director, Immunology. Dr. Keating will lead clinical development of GigaGen’s recombinant hyperimmune gammaglobulin product in collaboration with pharmaceutical partner Grifols. Read the full press release.
GigaGen CEO David Johnson to Present on the Power of Surge Technology to Discover Unique Immuno-oncology Antibodies at 14th Annual PEGS Summit
News, UncategorizedGigaGen Inc., a biopharmaceutical company developing novel antibody therapies, today announced that David Johnson, Ph.D., Founder and Chief Executive Officer, will present on the discovery of unique and functional antibodies utilizing Surge technology at the 14th Annual PEGS Summit. Dr. Johnson’s invited podium presentation is titled “Discovery of High-Affinity Human PD-1 and LAG-3 Antibodies Using […]
GigaGen CEO David Johnson to Present Data from Surge Platform at American Association for Cancer Research Annual Meeting 2018
News, UncategorizedGigaGen Inc., a biopharmaceutical company developing novel antibody therapies, today announced that David Johnson, Ph.D., chief executive officer, will present data from the company’s proprietary Surge platform at the American Association for Cancer Research (AACR) Annual Meeting 2018. The conference will take place April 14-18, 2018, at the McCormick Place in Chicago. Read the full […]
Nature Biotechnology: GigaGen Recognized as One of the Top Biotech Startups Funded in 2017
News, UncategorizedOur annual survey highlights how immune-oncology and screens based on the application of cutting-edge omics technologies are providing a launchpad for a succession of startups interrogating biology across biomedicine. Read the full story.